Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P1JI
|
|||
| Former ID |
DNC001514
|
|||
| Drug Name |
Wortmannin
|
|||
| Synonyms |
wortmannin; 19545-26-7; Wartmannin; KY 12420; Antibiotic SL-2052; SL-2052; UNII-XVA4O219QW; NSC221019; XVA4O219QW; MLS002703028; CHEMBL428496; CHEBI:52289; Wortmannin, 98%; Pi 3-Kinase Inhibitor; NSC 627609; BRN 0067676; (1S,6bR,9aS,11R,11bR)-9a,11b-dimethyl-1-[(methyloxy)methyl]-3,6,9-trioxo-1,6,6b,7,8,9,9a,10,11,11b-decahydro-3H-furo[4,3,2-de]indeno[4,5-h]isochromen-11-yl acetate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Terminated | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H24O8
|
|||
| Canonical SMILES |
CC(=O)OC1CC2(C(CCC2=O)C3=C1C4(C(OC(=O)C5=COC(=C54)C3=O)COC)C)C
|
|||
| InChI |
1S/C23H24O8/c1-10(24)30-13-7-22(2)12(5-6-14(22)25)16-18(13)23(3)15(9-28-4)31-21(27)11-8-29-20(17(11)23)19(16)26/h8,12-13,15H,5-7,9H2,1-4H3/t12-,13+,15+,22-,23-/m0/s1
|
|||
| InChIKey |
QDLHCMPXEPAAMD-QAIWCSMKSA-N
|
|||
| CAS Number |
CAS 19545-26-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
130227, 493589, 841033, 7980310, 8137238, 8884974, 11406228, 14929829, 16077138, 17396178, 21317840, 24278777, 26746624, 26756872, 37505411, 46493712, 46515542, 47212748, 47275094, 47646136, 49854219, 50111471, 53789920, 53799221, 56310781, 56313361, 57401357, 57581479, 68532900, 75303630, 85787298, 88783027, 92310152, 92763426, 93575765, 99301064, 99444530, 103174804, 104539627, 119501670, 127324586, 127324587, 127324588, 127324589, 127324590, 129006930, 134338914, 134340680, 135023272, 136342523
|
|||
| ChEBI ID |
CHEBI:52289
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6060). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007058) | |||
| REF 3 | Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun. 2003 Sep 5;308(4):764-9. | |||
| REF 4 | The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9. | |||
| REF 5 | Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 2002 Aug 15;62(16):4671-7. | |||
| REF 6 | Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 2002 Jun 7;294(2):384-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.